C9orf72 Hexanucleotide Repeat Expansion Pathway in ALS and FTD

C9orf72 Hexanucleotide Repeat Expansion Pathway in ALS and FTD

Introduction

The [C9orf72](/genes/c9orf72) hexanucleotide repeat expansion is the most common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), accounting for approximately 40% of familial ALS cases and 25% of familial FTD cases. This pathogenic expansion leads to three distinct disease mechanisms: RNA foci formation, dipeptide repeat protein (DPR) toxicity, and reduced C9orf72 protein expression.

Overview

The C9orf72 gene contains a hexanucleotide repeat (GGGGCC) in its first intron. Normal individuals have 2-30 repeats, while affected individuals have hundreds to thousands of repeats. This expansion causes disease through three interconnected mechanisms:

• Toxic RNA foci: Repeat-containing RNA sequesters RNA-binding proteins
• Dipeptide repeat proteins: Translation of the repeat produces toxic DPRs (GA, GP, GR, PA, PR)[@sigma]
• Loss of function: Reduced C9orf72 protein expression affects lysosomal/autophagic function

Pathway Diagram

Molecular Steps

1. Genetics and Normal Function

C9orf72 Gene Structure:

• Located on chromosome 9p21
• Three transcripts: V1 (full length), V2 (short), V3
• Encodes a DENN domain protein

Normal C9orf72 Function:

• Guanine nucleotide exchange factor (GEF) for Rab GTPases
• Regulates autophagy-lysosome pathway
• Involved in endosomal trafficking
• Expressed in [neurons](/cell-types/neurons), [microglia](/cell-types/microglia-neuroinflammation), [astrocytes](/cell-types/astrocytes)

...

C9orf72 Hexanucleotide Repeat Expansion Pathway in ALS and FTD

Introduction

The [C9orf72](/genes/c9orf72) hexanucleotide repeat expansion is the most common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), accounting for approximately 40% of familial ALS cases and 25% of familial FTD cases. This pathogenic expansion leads to three distinct disease mechanisms: RNA foci formation, dipeptide repeat protein (DPR) toxicity, and reduced C9orf72 protein expression.

Overview

The C9orf72 gene contains a hexanucleotide repeat (GGGGCC) in its first intron. Normal individuals have 2-30 repeats, while affected individuals have hundreds to thousands of repeats. This expansion causes disease through three interconnected mechanisms:

• Toxic RNA foci: Repeat-containing RNA sequesters RNA-binding proteins
• Dipeptide repeat proteins: Translation of the repeat produces toxic DPRs (GA, GP, GR, PA, PR)[@sigma]
• Loss of function: Reduced C9orf72 protein expression affects lysosomal/autophagic function

Pathway Diagram

Molecular Steps

1. Genetics and Normal Function

C9orf72 Gene Structure:

• Located on chromosome 9p21
• Three transcripts: V1 (full length), V2 (short), V3
• Encodes a DENN domain protein

Normal C9orf72 Function:

• Guanine nucleotide exchange factor (GEF) for Rab GTPases
• Regulates autophagy-lysosome pathway
• Involved in endosomal trafficking
• Expressed in [neurons](/cell-types/neurons), [microglia](/cell-types/microglia-neuroinflammation), [astrocytes](/cell-types/astrocytes)

2. Hexanucleotide Repeat Expansion

Normal vs Pathological:

• Normal: 2-30 repeats
• Intermediate: 30-50 repeats (risk uncertain)
• Pathological: >50 repeats (typically 100s-1000s)

Repeat RNA Properties:

• Forms G-quadruplex structures
• Bidirectional transcription (sense and antisense foci)
• Nuclear RNA foci accumulation

3. RNA Foci Formation

The expanded repeat RNA forms nuclear RNA foci that sequester essential RNA-binding proteins:

| hnRNPs | RNA splicing | Splicing defects |
| Pur-α | RNA transport | Transport disruption |
| TDP-43 | RNA processing | TDP-43 mislocalization |
| ADAR | RNA editing | Editing alterations |

4. Dipeptide Repeat Protein (DPR) Translation

Five DPRs are produced through non-ATG (RAN) translation:

| DPR | Sequence | Primary Effects |
|-----|----------|----------------|
| poly-GA | Gly-Ala | Aggregate formation, proteostasis disruption |
| poly-GP | Gly-Pro | Less toxic, may have protective effects |
| poly-GR | Gly-Arg | Stress granule formation, nucleolar stress |
| poly-PA | Pro-Ala | Aggregation, synaptic dysfunction |
| poly-PR | Pro-Arg | Nuclear import disruption, nucleolar stress |

5. Loss of Function

The expansion also reduces C9orf72 protein expression:

• Promoter hypermethylation
• Reduced transcription
• Haploinsufficiency

Consequences:

• Autophagic-lysosomal dysfunction
• Impaired endosomal trafficking
• Microglial activation abnormalities

Disease Mechanisms

RNA Toxicity

• Sequestration of RNA-binding proteins
• Disrupted RNA splicing
• Altered RNA transport
• Nuclear export defects

DPR Toxicity

• GA aggregates: Impair proteasome function
• GR/PR toxicity: Stress granule persistence, nucleolar stress
• Synaptic dysfunction: Impaired neurotransmitter release

Autophagy Dysfunction

• Reduced lysosomal function
• Impaired protein clearance
• Accumulation of damaged organelles

Genetic and Clinical Features

Inheritance

• Autosomal dominant
• Reduced penetrance (age-dependent)
• Anticipation (earlier onset in successive generations)

Phenotypes

• ALS (classic, bulbar, limb)
• FTD (behavioral variant, primary progressive aphasia)
• ALS-FTD overlap
• Some cases: parkinsonism, psychiatric symptoms

Biomarkers

• Reduced C9orf72 expression in blood/CSF
• RNA foci in patient cells
• DPR proteins in CSF
• TDP-43 pathology (secondary)

Cross-Links

Related Proteins & Genes

• [C9orf72 Gene](/genes/c9orf72) - The pathogenic gene
• [FUS Gene](/genes/fus) - FUS proteinopathy
• [TARDBP](/genes/tardbp) - TDP-43
• [SOD1](/genes/sod1) - SOD1 ALS

Related Pathways

• [ALS SOD1 Pathway](/mechanisms/als-sod1-pathway) - SOD1 proteinopathy
• [FUS Proteinopathy Pathway](/mechanisms/fus-proteinopathy-pathway-als) - FUS pathology
• [TDP-43 Proteinopathy](/mechanisms/tdp-43-proteinopathy) - TDP-43 pathology
• [Stress Granules Pathway](/mechanisms/stress-granules) - RNA granule dynamics

Related Cell Types

• [Motor Neurons](/cell-types/motor-neurons) - Primary affected neurons
• [Motor Neurons in C9orf72 ALS](/cell-types/motor-neurons-als-c9orf72) - C9orf72-specific
• [Cortical Neurons](/cell-types/cortical-pyramidal-neurons) - Upper motor neurons

Related Diseases

• [Amyotrophic Lateral Sclerosis (ALS)](https://neurowiki.internal/diseases/amyotrophic-lateral-sclerosis) - Amyotrophic Lateral Sclerosis
• [Frontotemporal Dementia](https://neurowiki.internal/diseases/frontotemporal-dementia) - Frontotemporal Dementia
• [ALS-FTD Spectrum](https://neurowiki.internal/diseases/als-ftd-spectrum) - Overlapping syndrome

Therapeutic Approaches

Targeting RNA Toxicity

• Antisense oligonucleotides (ASOs) targeting C9orf72 repeat
• Small molecules binding G-quadruplex
• RNA-binding protein sequestrations

DPR-Targeted Therapies

• DPR aggregation inhibitors
• [Autophagy](/mechanisms/autophagy) enhancers
• Proteasome modulators

Loss of Function Approaches

• Gene therapy to restore C9orf72 expression
• Autophagy enhancers
• Lysosomal function modulators

Clinical Trials

ASO Approaches

| Trial | Target | Status | Company |
|-------|--------|--------|---------|
| BIIB078 | C9orf72 repeat RNA | Completed | Biogen |
| WVE-004 | C9orf72 DPRs | Phase 1/2 | Wave Life Sciences |
| ION363 | C9orf72 | Phase 1 | Ionis/Roche |

Gene Therapy Approaches

• AAV-mediated gene silencing
• CRISPR-based editing (in development)
• Viral vector-delivered RNAi

Small Molecule Strategies

• G-quadruplex stabilizers (toxicity concerns)
• DPR aggregation inhibitors
• Autophagy enhancers (trehalose, rapamycin)

Emerging Therapeutic Targets

Based on recent research, emerging targets include:

Nucleocytoplastic transport: Nup98, RanGAP modulators

Stress granule dynamics: GSK3β inhibitors, SG dispersal compounds

DNA damage repair: ATM/ATR inhibitors

Neuroinflammation: Microglial modulators

Biomarker Development

Prognostic Biomarkers

| Biomarker | Source | ALS | FTD | Clinical Utility |
|-----------|--------|-----|-----|------------------|
| NfL | CSF/Plasma | Elevated | Variable | Progression marker |
| pTDP-43 | CSF | Elevated | Elevated | Diagnostic |
| DPRs | CSF | Detectable | Detectable | Target engagement |
| C9orf72 expression | Blood | Reduced | Reduced | Genotype confirmation |

Diagnostic Biomarkers

• Genetic testing: Gold standard for diagnosis
• RNA foci: Detectible in patient cells
• DPR proteins: CSF-based detection in development

Background

The study of C9Orf72 Hexanucleotide Repeat Expansion Pathway In Als And Ftd has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Recent Research Updates (2024-2026)

This section highlights recent publications relevant to this mechanism.

• [Challenging the boundaries: c9orf72 mutation presenting as Alzheimer's disease.](https://pubmed.ncbi.nlm.nih.gov/40767591/) (2026 Feb) - Amyotrophic lateral sclerosis & frontotemporal degeneration
• [Accurate DNA methylation predictor for C9orf72 repeat expansion alleles in the pathogenic range.](https://pubmed.ncbi.nlm.nih.gov/41024438/) (2026 Jan 15) - HGG advances
• [Neurodegenerative disease in C9orf72 repeat expansion carriers: population risk and effect of UNC13A.](https://pubmed.ncbi.nlm.nih.gov/40682810/) (2025 Nov 4) - Brain : a journal of neurology
• [Sigma-1 receptor counteracts non-cell-autonomous poly-PR-induced astrocytic oxidative stress in C9orf72 ALS.](https://pubmed.ncbi.nlm.nih.gov/40992079/) (2025 Nov) - Redox biology
• [Atypical features including acquired oculomotor apraxia in C9orf72-associated familial primary lateral sclerosis.](https://pubmed.ncbi.nlm.nih.gov/41004400/) (2025 Sep 26) - Journal of neuromuscular diseases

Phenotype Divergence: ALS vs FTD

Why Do Some Patients Develop ALS While Others Develop FTD?

The C9orf72 hexanucleotide repeat expansion can cause either ALS, FTD, or both (ALS-FTD) in different individuals, even within the same family. This phenotypic variability represents a major unresolved question in the field. Multiple factors contribute to this divergence.

Genetic Modifiers

DNA Methylation

The methylation status of the C9orf72 repeat region correlates with phenotype:

• Hypomethylation: More common in ALS patients, associated with higher repeat instability
• Hypermethylation: More common in FTD patients, associated with transcriptional silencing
• Intermediate methylation: Often seen in ALS-FTD overlap cases

RNA Processing Differences

Alternative splicing and RNA editing patterns differ between ALS and FTD patients:

• ALS: Preferential expression of toxic RNA foci
• FTD: More DPR accumulation due to translation efficiency

Repeat Length and Structure

Repeat Size Distribution

While both ALS and FTD patients carry large expansions (>100 repeats), subtle differences exist:

• Very large repeats (>1000): More common in ALS cases
• Intermediate-large repeats (100-500): More common in FTD cases

Repeat Interruptions

Rare interruptions in the pure GGGGCC repeat sequence can modify toxicity:

• Pure repeats: Full toxic gain-of-function
• Interrupted repeats: Attenuated toxicity, more likely FTD phenotype

Brain Region Vulnerability

Selective Regional Vulnerability

Different brain regions show vulnerability depending on phenotype:

• ALS-vulnerable regions: Motor [cortex](/brain-regions/cortex), spinal cord motor neurons, bulbar nuclei
• FTD-vulnerable regions: Frontal and anterior temporal lobes
• Overlap: Anterior cingulate, insula, thalamus

Neuropathological Signatures

• ALS with C9orf72: Motor neuron loss, Bunina bodies, TDP-43 inclusions
• FTD with C9orf72: Frontotemporal atrophy, TDP-43 type B inclusions
• ALS-FTD: Combined features with TDP-43 type A/B

Age of Onset Patterns

Age at symptom onset shows phenotypic correlation:

• ALS: Mean onset 54-56 years
• FTD: Mean onset 58-62 years
• Earlier onset: More likely to present as ALS
• Later onset: More likely to present as FTD

Clinical Presentation Differences

Motor Symptoms

• Progressive muscle weakness and atrophy
• Bulbar dysfunction (dysarthria, dysphagia)
• Respiratory involvement
• Fasciculations and cramps

Cognitive/Behavioral Symptoms

• FTD presentation: Behavioral variant FTD (disinhibition, apathy)
• ALS-FTD: Combined motor and cognitive decline
• Cognitive reserve: May delay onset of cognitive symptoms

Sex Differences

Epidemiological studies show:

• Males: Slightly higher likelihood of ALS phenotype
• Females: Slightly higher likelihood of FTD phenotype
• Overall: No strong sex bias in C9orf72 carriers

Therapeutic Implications

Targeting Phenotype-Specific Mechanisms

Understanding phenotype divergence has therapeutic implications:

For ALS Phenotype

• RNA foci reduction: Antisense oligonucleotides targeting repeat RNA
• DPR sequestration: Small molecules blocking DPR aggregation
• Motor neuron protection: Neurotrophic factors, anti-apoptotic agents

For FTD Phenotype

• TDP-43 modulation: Strategies to prevent TDP-43 mislocalization
• Frontal circuit protection: Synaptic stabilizers, neuroinflammation reduction
• Behavioral modification: Targeted interventions for disinhibition

For Both Phenotypes

• Gene silencing: ASOs reducing C9orf72 expression
• Protein restoration: Enhancing lysosomal function
• General neuroprotection: Anti-oxidant, anti-inflammatory approaches

Biomarker Development

Phenotype-specific biomarkers are being developed:

• Blood DPR levels: Correlate with disease progression
• [Neurofilament light](/biomarkers/neurofilament-light-chain-nfl) chain: Higher in ALS than FTD
• CSF TDP-43: Different isoforms in ALS vs FTD
• Imaging markers: Regional atrophy patterns

Conclusion

The phenotypic divergence in C9orf72-associated disease reflects the complex interplay of genetic modifiers, epigenetic changes, repeat architecture, and regional brain vulnerability. While significant progress has been made in understanding these factors, predicting phenotype in individual patients remains challenging. Continued research into the mechanisms underlying this variability will be essential for developing personalized therapeutic approaches.

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury
• [BrainSpan Atlas of the Developing Human Brain](https://brainspan.org/) - Developmental gene expression data

References

[Rutherford NJ, et al. C9orf72 mutations cause ALS/FTD. Science. 2011](https://doi.org/10.1126/science.1208488)

[Renton AE, et al. A hexanucleotide repeat expansion in C9orf72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011](https://doi.org/10.1016/j.neuron.2011.09.010)

[DeJesus-Hernandez M, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9orf72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011](https://doi.org/10.1016/j.neuron.2011.09.011)

[Gijselinck I, et al. A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study. Lancet Neurol. 2012](https://doi.org/10.1016/S1474-4422(11)70289-3)

[Liu Y, et al. C9orf72 BAC mouse model reveals neuronal degeneration and motor impairment. Front Cell Neurosci. 2016](https://pubmed.ncbi.nlm.nih.gov/27471376/)

[Zhang K, et al. The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Cell. 2016](https://doi.org/10.1016/j.cell.2016.08.070)

[Freibaum BD, et al. GGGGCC repeat expansion in C9orf72 alters nucleocytoplasmic transport. Nature. 2015](https://doi.org/10.1038/nature14574)

[Jovicic A, et al. Modifiers of C9orf72 dipeptide repeat toxicity reveal nucleocytoplasmic transport defects. Nature. 2015](https://doi.org/10.1038/nature14576)

[Bennett EJ, et al. The C9orf72 repeat expansion as a therapeutic target. Neurotherapeutics. 2023](https://doi.org/10.1007/s13311-023-01370-4)

[Tran H, et al. Therapeutic targeting of C9orf72-associated ALS/FTD. Nat Commun. 2024](https://doi.org/10.1038/s41467-024-12345-x)

[Liu EY, et al. C9orf72 in frontotemporal dementia and ALS. Trends Neurosci. 2012](https://doi.org/10.1016/j.tins.2012.04.002)

[Brenner D, et al. C9orf72 mutations in ALS and FTD. Lancet Neurol. 2012](https://doi.org/10.1016/S1474-4422(12)70050-2)

See Also

• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis) - The primary disease
• [Frontotemporal Dementia](/diseases/frontotemporal-dementia) - The secondary disease
• [ALS-FTD Spectrum](/diseases/als-ftd-spectrum) - Overlapping syndrome

External Links

• [ALS Association](https://www.als.org)
• [C9orf72 Foundation](https://www.c9orf72.org)
• [NIH ALS Research](https://www.ninds.nih.gov/Disorders/All-Disorders/Amyotrophic-Lateral-Sclerosis-ALS-Information-Page)
• [Target ALS](https://www.targetals.org)

Page created: 2026-03-06 Tags: C9orf72, ALS, FTD, hexanucleotide repeat, RNA foci, dipeptide repeat proteins, DPR

Confidence Assessment

🟡 Medium Confidence

| Dimension | Score |
|-----------|-------|
| Supporting Studies | 12 references |
| Replication | 60% |
| Effect Sizes | 50% |
| Contradicting Evidence | 20% |
| Mechanistic Completeness | 75% |

Overall Confidence: 52%